Viewing stories from July, 2014
Appendix 4C - Quarterly Cashflow Statement
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2014.
VivaGel® condom receives TGA device certification - Launch preparations to follow
Starpharma today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel® condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.
FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
Starpharma today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel® bacterial vaginosis (BV) product for the prevention of recurrent BV.